DBV is formerly owned by Sofinnova Partners, through Sofinnova Capital VI, since 2010.

When did Sofinnova Partners acquire DBV?

Sofinnova Partners acquired DBV in 2010 and exited after 4 years.

Yes. DBV was exited in 2014 via IPO.

Home/Companies/Biotech/DBV

DBV

Biotech·

France·Exited 2014·Held 4yr

DBV is a healthcare / biotech company, headquartered in France.

Entry

2010

Hold

4yr

Exit

2014

Est. EV

–

Investor

Sofinnova Partners

Key facts

HQFrance

SectorHealthcare / Biotech

Food allergy biotech. IPO on Euronext/Nasdaq in 2014 IPO Mar 2014 Euronext Paris and Oct 2014 NASDAQ (DBVT).

See the full ownership history.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Full fund context: vintage, strategy, region

Exit details: type, year, MOIC (buyer on Pro)

Start free

Already a member? Sign in

More from Sofinnova Capital VI

Other portfolio companies in the same fund.

Omthera Pharmaceuticals

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Last updated April 2026 · Sourced from public filings